Efficacy of Marine By-product Hydrolysate on the Reduction of Atopic Dermatitis Symptoms

Prior treatment

• Topical treatment with immunomodulators (tacrolimus or pimecrolimus) in the three months prior to registration;
• Recent change, forecast of initiation of an hormonal treatment or change of the usual hormonal treatment during the study or 3 months before the starting of the study;
• Subject having undergone a surgery under general anesthesia within the previous month;
• Exposure in UVA ray sunbed during the 3 months before the start of the study on the experimental area or during the study;

Other illness

• Known history of chronic disease such as congenital heart disease, liver or kidney disease, or immune deficiency;
• Acute or chronic infectious diseases;
• Subjects suffering Alimentary/Eating disorders (i.e. bulimia, psychogenic eating disorders, etc.)
• Allergy or intolerance to any ingredient of the experimental food supplement;
• Subjects with diabetes mellitus;
• Fish and/or iodine allergy;
• Intestinal conditions or disorders (Crohn's disease, colitis, irritable bowel syndrome, intestinal malabsorption...)

Other

• Pregnant or nursing woman or woman planning to get pregnant during the study;
• Cutaneous marks on the experimental areas, which could interfere with the assessment of skin reactions;
• Subjects who have participated in the last 3 months or are currently participating in another clinical trial that may interfere with the evaluation of the primary endpoint (endpoint AD);
• Current administration of antibiotics;
• Application of moisturizing products on the experimental area the day of the inclusion of the study;
• Not meet inclusion criteria;
• Those undergoing aesthetic medicine (fillers, hyaluronic acid injections, botox) that could interference in the experimental area;
• Subjects having frequent stomach burn;
• Subjects protected by the law;
• Subject employed by EUROFINS PRODUCT TESTING, COSMETICS \& PERSONAL CARE SPAIN, S.L.U.

• Phototype: I to V;
• Subjects with atopic skin (with at least 1 visible xerosis + inflammation on the body);
• Subjects with a history background of asthma, rhinitis and/or allergic conjunctivitis;
• Subjects with SCORAD between 8 and 30 (at least 50% or more having around 8-10);
• Subjects with BMI between 20 and 30 kg/m2 (limits included);
• Subjects who have not recently participated in another similar study;
• Willingness to take supplements for the duration of the study;
• Willingness not to use products likely to interfere with the test product (collagen, hyaluronic acid, anti-stress products);
• Willingness not to change lifestyle habits;
• Willingness to avoid intensive UV exposure;
• Use of contraception that should not be modified during the study.
• Healthy subject;
• Mentally healthy subject according to Investigator's opinion;
• Subject having given his/her free informed, written consent;
• Subject agrees to taking photograph and then use the image after its pseudonymization;
• Subject willing to adhere to the protocol and study procedures;
• Subject able to understand the study;
• Subject available to attend the study visits.